30 young males performed inspiratory breath holdings during expectation of an aversive stimulus and at relative rest. The consecutive R-R intervals of the ECG from breath-hold trial were analysed via spectral analysis of time series. Following parameters were ascertained for each breath holding: mean R-R interval, total R-R interval variability, breath-hold time and relative variability in three spectral bands 3-8 s, 8-12 s and 12-18 s. Neither of these variables was influenced by expectation of an aversive stimulus. The data were subsequently analysed by means of multivariate analysis. Three distinct frequency components were selected according to both histogram data and multivariate analysis. Their modal periods were 5-6 s, 12 s and 16 s respectively. The 8-12 s component of R-R interval variability dominated during breath holdings. The 3-8 s band bore a negative relationship to breath-hold time.
- MeSH
- Acoustic Stimulation MeSH
- Analysis of Variance MeSH
- Adult MeSH
- Respiration * MeSH
- Electric Stimulation MeSH
- Electrocardiography * MeSH
- Humans MeSH
- Mathematics MeSH
- Stress, Psychological physiopathology MeSH
- Heart Rate MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
BACKGROUND/AIMS: The activity of oxaliplatin (OHP) and irinotecan (CPT) alone or in combination with 5-fluorouracil (5-FU) in advanced colorectal cancer is comparable, but there are limited data on the effectiveness of oxaliplatin in patients pretreated by irinotecan. METHODOLOGY: We have analyzed retrospectively the survival of 77 consecutive advanced colorectal cancer patients treated with OHP after previous CPT therapy. Multivariate analysis was performed by Cox regression method, with the results expressed as hazard ratio (HR). RESULTS: The median survival from the start of OHP therapy was 10.7 months (1-year survival 43%). The median survival was not reached in 10 patients treated by hepatic arterial infusion of OHP (>10.6 months). The median survival from the diagnosis of advanced/metastatic disease was 34.3 months. On multivariate analysis, hemoglobin <125g/L (HR=2.42), neutrophils <5200 per microL (HR=0.36), duration of advanced/metastatic disease <21 months (HR=2.40) and interval from last CPT administration <3 months (HR=0.27) were statistically significant (p<0.05) independent predictors of survival from the start of OHP treatment, but only hemoglobin (HR=2.07), neutrophils (HR=0.32) and CEA <100microg/L (HR=0.44) were independent predictors of survival from the last CPT. There were 4 treatment-induced deaths after combination of OHP and raltitrexed (TOMOX). CONCLUSIONS: More than 40% of patients pretreated by irinotecan survived 1 year after start of OHP therapy. The therapy was similarly effective as a second or higher line of treatment. Hemoglobin levels and neutrophil count were independent factors associated with survival. The number of toxic deaths observed after TOMOX is alarming.
- MeSH
- Survival Analysis MeSH
- Analysis of Variance MeSH
- Time Factors MeSH
- Fluorouracil therapeutic use MeSH
- Risk Assessment MeSH
- Irinotecan MeSH
- Camptothecin analogs & derivatives therapeutic use MeSH
- Colorectal Neoplasms mortality pathology surgery MeSH
- Humans MeSH
- Neoplasm Recurrence, Local drug therapy mortality pathology MeSH
- Multivariate Analysis MeSH
- Follow-Up Studies MeSH
- Organoplatinum Compounds therapeutic use MeSH
- Oxaliplatin MeSH
- Palliative Care methods MeSH
- Probability MeSH
- Proportional Hazards Models MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Retrospective Studies MeSH
- Drug Administration Schedule MeSH
- Neoplasm Staging MeSH
- Treatment Outcome MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Fluorouracil MeSH
- Irinotecan MeSH
- Camptothecin MeSH
- Organoplatinum Compounds MeSH
- Oxaliplatin MeSH
